First prescriptions for Sofdra™ (sofpironium) topical gel, 12.45% have shipped to patients after having successfully been diagnosed via telemedicine and cleared insurance approvals. Following sales force deployment, a wider digital program will begin in Q2 2025.
Botanix Founder and Board Executive Director Matt Callahanwill be a featured presenter at the Bell Potter Healthcare Conference 2024 on Tuesday, 19 November. A copy of the presentation being used is attached to the ASX press release.
Ascent Health, second largest Payer (insurer) organisation in the US, will now cover Sofdra™ (sofpironium) topical gel, 12.45%. Ascent represents approximately 65 million (or nearly 40%) of US commercial lives.
Quarterly Activity Report and 4C Quarterly Cash Flow Report released. At quarter end, Botanix held A$68.67 million cash with no debt (other than typical trade creditors), which will fund operations as it ramps up manufacturing and sales activity of its Sofdra product.
While in Australia last month, Botanix CEO Dr Howie McKibbon spoke with Bell Direct’s Grady Wulff about the Company’s FDA-approved product, Sofdra™, the competitive landscape in dermatology, and the outlook for Botanix over the next 12 months.
Take a look:
Botanix CEO Howie McKibbon recently visited Australia to meet with investors, and to present at the ASX Small and Mid-Cap Conference and the E&P Small Cap Healthcare Conference.
During his visit, he was interviewed in the Ausbiz studio to discuss the Company’s comprehensive commercialisation plans for Sofdra™. Take a look:
Botanix provides a staffing update as it prepares for the planned launch of Sofdra™ (sofpironium) 12.45% in Q4 CY2024 and announces issuance of its Notice of Meeting for the Annual General Meeting on 4 November 2024 which was released to ASX today.
Botanix CEO Howie McKibbon will be a featured presenter at ASX Small and Mid-Cap Conference on Wednesday, 25 September, and the E&P Small Cap Healthcare Conference on Thursday, 26 September. Botanix will also conduct one-on-one updates with investors.
Click here to view ASX Release.
Health Editor for The Australian Financial Review, Michael Smith, has featured Botanix Pharmaceuticals in an article titled The five pharma stocks exciting investors.
Smith speaks to leading fund managers about their experiences and professional insights when navigating the biotechnology sector – which they say is back in favour for those willing to sort the ‘winners from the losers’ and ride the wave of success stories like CSL.
Here is an excerpt, quoting Rory Hunter, a portfolio manager for SG Hiscock’s Medical Technology Fund:
‘“It requires a diversified approach to the sector. Once the IP is validated, you are moving into commercialisation and past regulatory approvals.”
‘He likes Botanix for this reason. Its treatment for hyperhidrosis, or severe underarm sweating, affects a large part of the population, and its Japanese partner has already commercialised its treatment. “They will accelerate revenues and profitability. While their IP isn’t quite as exciting, the market they are addressing is significant,” he says.’
Video is now available of the Company’s Commercial Day Webinar recorded on 17 September. In the presentation, the Botanix commercial team and their guests provide market insights and a comprehensive update on the launch plans for Sofdra™.
